ERBB2 and pneumonitis: Pneumonitis, also referred to as interstitial lung disease, is a well-known AE associated with several anti-HER2 agents.16, 17, 18, 19 In our analysis, pneumonitis occurred in 1.0% of patients in cohort 1 and 2.2% of patients in cohort 2.